FDA Inspection 1257609 — Intercept Pharmaceuticals, Inc.
The FDA completed an inspection of Intercept Pharmaceuticals, Inc. on Nov 14, 2024 in Morristown, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 14, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Morristown, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)